Menu
Recruiting NCT07173543

IH, Brain Health, and T2D

No phase Interventional Type 2 Diabetes Aging

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Intermittent Hypoxia 1 (IH1), Intermittent Hypoxia 2 (IH2), SHAM - normoxia.
Who it may be relevant to
Registry conditions: Type 2 Diabetes, Aging. Basic parameters: 60 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Intermittent Hypoxia Training and Cerebrovascular Health in Older Adults With Type 2 Diabetes

Overview

The purpose of this study is to use a randomized, placebo-controlled study design to rigorously examine the therapeutic potential of intermittent hypoxia (IH) for improving cerebrovascular health in older adults with and without type 2 diabetes mellitus (T2DM).

Detailed description

Aging is considered a major risk factor for the development of various cardio- and cerebrovascular related diseases, with vascular endothelial dysfunction representing one of the earliest vascular complications. Age-related cerebrovascular endothelial dysfunction contributes to a progressive decrease in cerebral blood flow, which is associated with lower measures of cognitive function, including information-processing speed, executive function, and global cognition in older adults. Similar to aging, type 2 diabetes mellitus (T2DM) also negatively impacts vascular endothelial function. There is a large body of evidence that clearly demonstrates there is an interplay between aging and T2DM and that the presence of both risk factors together promotes greater endothelial dysfunction than that of either condition alone. In this context, certain measures of cerebral blood flow are reduced to a greater extent in older individuals with T2DM compared to those without. Moreover, the exaggerated cerebral perfusion deficits frequently observed among older adults with T2DM are linked to cognitive decrements. To this point, the rate of cognitive decline due to aging is increased 1.5 to 2.0-fold in individuals with T2DM. Taken together, older adults with T2DM are at greater risk for developing dementia and Alzheimer's disease when compared age-matched controls.

Exploration of non-pharmacological therapies for the improvement of cerebrovascular health and cognition have become more common over the past decade. Intermittent hypoxia (IH) is a therapeutic intervention that combines multiple, brief (\~1-10 minutes) episodes of moderate hypoxia, interspersed with episodes of normoxia. In preclinical and human studies, repeated bouts of IH improve measures of respiratory, autonomic, cardio-, and cerebrovascular health. The investigators previously demonstrated that cerebral blood flow is increased with each episode of hypoxia and a single session of IH improves nitic oxide (NO) mediated endothelial function in the internal carotid artery (ICA; major supplier of overall brain blood flow) of young adults. While cerebral blood flow is also augmented during a single session of IH in older adults, the magnitude of change appears to be less, which might suggest older adults with and without T2DM may need repeated sessions of IH for improvements in cerebrovascular health to occur. The investigator's central hypothesis is that experimental use of IH will effectively and progressively improve cerebrovascular health and cognition in older adults with T2DM. Specifically, the investigators will evaluate the interplay between aging and T2DM and how it influences cerebral endothelial function as well as the cerebrovascular responses to IH (Aim 1) and test the effectiveness of IH training for the improvement of cerebrovascular health in older adults living with diabetes (Aim 2). Collectively, the proposed studies will provide 1) novel understanding of cerebrovascular function in older adults with and without T2DM, and 2) important insight into the therapeutic potential of IH for improving cerebrovascular health and cognition in older adults living with T2DM.

Interventions

  • Other Intermittent Hypoxia 1 (IH1)
    Intermittent Hypoxia 1 (IH1): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 8 weeks
  • Other Intermittent Hypoxia 2 (IH2)
    Intermittent Hypoxia 1 (IH2): 5 cycles of normoxia (4 minutes)/hypoxia (6 minutes) per session. 3 sessions per week for 4 weeks
  • Other SHAM - normoxia
    Participants will receive normoxia (no hypoxia) over 50 minutes.

Primary outcome measures

  • Internal Carotid Artery (ICA) shear-mediated dilation [Time frame: Baseline and post 2-,4-,5-,6-, and 8-weeks]
  • Cerebral blood flow responsiveness [Time frame: Baseline and after 50 minutes of IH or SHAM]
  • Cognitive function testing [Time frame: Baseline and post 4- and 8-weeks]

Eligibility criteria

For 30 patients with documented Type 2 diabetes

Inclusion criteria

  • Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
  • Age is > or = 60 and < or = 85 years of age
  • Documented Type 2 diabetes
  • Scoring 26 or higher on the MoCA test

Exclusion criteria

  • diagnosis of type 2 diabetes < 1 year prior to enrollment
  • HbA1c <6.5% or >10.0%
  • body mass index > 40 kg/m 2
  • incident cardiovascular events in the last year (heart attack, stroke)
  • symptomatic coronary artery disease and/or heart failure
  • uncontrolled hypertension
  • obstructive sleep apnea
  • pulmonary disease
  • dementia
  • renal impairment with creatinine clearance (eGFR) of <60 ml/min
  • smoking or history of smoking within past one year

30 nondiabetic control subjects will also be studied.

Inclusion criteria

  • Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
  • Age is > or = 60 and < or = 85 years of age
  • Scoring 26 or higher on the MoCA test

Exclusion criteria

  • Diagnosis of diabetes (Type 1 or Type 2)
  • body mass index > 40 kg/m2
  • incident cardiovascular events in the last year (heart attack, stroke)
  • symptomatic coronary artery disease and/or heart failure
  • uncontrolled hypertension
  • obstructive sleep apnea
  • pulmonary disease
  • dementia
  • renal impairment with creatinine clearance (eGFR) of <60 ml/min
  • smoking or history of smoking within past one year

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

United States · 1 center
  • University of Iowa — Iowa City

Identifiers

NCT: NCT07173543 · 202505661

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗